logo

Compugen Ltd (CGEN)



Trade CGEN now with
  Date
  Headline
12/23/2020 7:03:29 AM Compugen Announces First Milestone In License Deal With AstraZeneca On Bispecific, Multi-specific Antibody Products
11/5/2020 7:07:55 AM Compugen Q3 Net Loss $7.8 Mln Or $0.09/shr Vs. Net Loss $6.5 Mln Or $0.10/shr Last Year
9/30/2020 7:18:54 AM Compugen Announces Addition Of Nils Lonberg To Scientific Advisory Board
9/8/2020 7:08:24 AM Compugen Doses First Patient In Phase 1/2 Triple Combination Study Of COM701 With Opdivo And Anti-TIGIT Antibody
8/28/2020 7:05:42 AM Compugen Says USPTO Granted A New Patent Covering The Composition Of Matter Of COM902
7/30/2020 7:26:40 AM Compugen Q2 Net Loss $6.2 Mln Or $0.08/shr Vs Net Loss $6.0 Mln Or $0.10/shr Last Year
7/30/2020 7:00:00 AM Compugen Reports Second Quarter 2020 Results (Press Release)
6/12/2020 10:52:13 AM Stock Alert: Compugen Jumps 9%
6/1/2020 7:08:06 AM Compugen: FDA Clears IND Application For Phase 1/2 Of COM701 With Bristol Myers Squibb's Opdivo And TIGIT Inhibitor
5/27/2020 7:02:38 AM Compugen Doses First Patient In COM701 Phase 1 Monotherapy Expansion Cohort
5/6/2020 7:17:25 AM Compugen Q1 Net Loss $7.1 Mln Or $0.10/shr Vs. Net Loss $8.4 Mln Or $0.14/shr Last Year
4/27/2020 6:03:11 AM Compugen Presents Data Update From Ongoing Phase 1 Trial Of COM701 At 2020 AACR Virtual Annual Meeting
4/22/2020 8:30:45 AM European Patent Office Grants Compugen A New Patent Forcomposition Of COM701 Or Backup Antibodies For Cancer